{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000003","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.310832+00:00","generated_at":"2026-05-28T03:30:38.693517+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas Medicine reports $270M cash, new in vivo preclinical data, and 2025-2027 strategic priorities","bullets":["Preliminary cash, equivalents, marketable securities ~$270M as of Dec 31, 2024; operational runway into Q2 2027.","Achieved in vivo editing of hematopoietic stem cells in non-human primates using proprietary tLNPs; further optimization underway.","Achieved proof of concept for AsCas12a LNP delivery in liver cells in non-human primates; also demonstrated upregulation in mice.","Anticipates declaring two in vivo development candidates by mid-2025: HSC for sickle cell/beta thalassemia and liver for undisclosed indication.","Strategic priorities through 2027: submit at least one IND/CTA by mid-2026, start human trials H2 2026, initiate late-stage trial H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000003","json":"https://secwatch.observer/filing/0001650664-25-000003.json","markdown":"https://secwatch.observer/filing/0001650664-25-000003.md","text":"https://secwatch.observer/filing/0001650664-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000003/0001650664-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000003/edit-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:30:38.693517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}